RNAi therapies for HCPs
RNAi therapies for HCPs

AMVUTTRA®triangle (vutrisiran) - RNAi Therapy

Select below to explore educational, scientific and clinical resources related to the licensed uses of our therapies in the UK

  AMVUTTRA® (vutrisiran)

View Prescribing Information

Explore clinical and educational resources related to the use of vutrisiran in adult patients with hereditary transthyretin amyloidosis with stage 1 or stage 2 polyneuropathy (hATTR-PN) or wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).

Resources

HELIOS-B-Phase-3.png
icon Title

A plain language summary of the HELIOS-B Study

icon Material type

Plain Language Summary

icon Description

A Plain Language Summary of the HELIOS-B Study of vutrisiran in ATTR-CM.

Preparation Date
March 2026
Job Code
MB-UK-00182
Retrieving data. Wait a few seconds and try to cut or copy again.
icon Title

HELIOS-B Phase 3 Study of vutrisiran in ATTR-CM

icon Material type

Slide Presentation

icon Description

A presentation on the HELIOS-B Study results of vutrisiran in ATTR-CM

Preparation Date
March 2026
Job Code
MB-UK-00180 

Explore Additional Resources and Support

Attr

Transthyretin Amyloidosis (ATTR)

To learn about Transthyretin (ATTR) Amyloidosis therapeutic area

Right Arrow
Medical call icon representing healthcare communication

Didn't Find What You Were Looking For?

Contact our medical team for scientific information, support, and resources

Right Arrow
Preparation Date
January 2026
Job Code
MB-UK-00035